Pfizer Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Pfizer Ltd. on BSE

Load latest

Pfizer Ltd.

19 May 2025

5235.00

0.23%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Outcome of Board Meeting

pdf

Pfizer Ltd.

13 May 2025

5235.00

0.23%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The …

BSE India

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 19, 2025 inter alia, to consider, approve and take on record the Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2025 and to consider recommendation of dividend, if any, for the Financial Year ended March 31, 2025.

pdf

Pfizer Ltd.

29 Apr 2025

5235.00

0.23%

Corp. Note

Pfizer Ltd - 500680 - Format of the Annual Disclosure to be made by an entity …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Pfizer Ltd 2 CIN NO. L24231MH1950PLC008311 3 Report filed for FY 2024-2025 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 0 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)0 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Prajeet NairDesignation :-Director Corporate Services and Company Secretary Name of the Chief Financial Officer :- Amit Agarwal Designation : -Executive Director - Finance & Chief Financial Officer Date: 29/04/2025

pdf

Pfizer Ltd.

11 Apr 2025

5235.00

0.23%

Company Update

Pfizer Ltd - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We furnish herewith certificate dated April 11, 2025 issued by KFin Technologies Limited for the quarter ended March 31, 2025.

pdf

Pfizer Ltd.

01 Apr 2025

5235.00

0.23%

Company Update

Pfizer Ltd - 500680 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Intimation regarding change in Senior Management Personnel.

pdf

Pfizer Ltd.

31 Mar 2025

5235.00

0.23%

SAST

Pfizer Ltd - 500680 - Closure of Trading Window

BSE India

We would like to inform you that the trading window of the Company shall remain closed from March 31, 2025 (close of business) till 48 hours after Audited Financial Results for the year ending March 31, 2025 are made public.

pdf

Pfizer Ltd.

29 Mar 2025

5235.00

0.23%

Company Update

Pfizer Ltd - 500680 - Update On Transfer And Assignment Of Pfizer'S Unexpired Leasehold Rights In …

BSE India

Update on Transfer and Assignment of MIDC Land and Buildings constructed thereon.

pdf

Pfizer Ltd.

19 Mar 2025

5235.00

0.23%

SAST

Pfizer Ltd - 500680 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India

pdf

Pfizer Ltd.

21 Feb 2025

5235.00

0.23%

Corp. Note

PFIZER LTD. - 500680 - Board Meeting Outcome for Marketing And Supply Agreement With Mylan Pharmaceuticals …

BSE India

Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane.

pdf